BaseLaunch announces a new partnership with AbbVie
Further strengthens BaseLaunch's global pharma industry partnerships
Further strengthens BaseLaunch's global pharma industry partnerships
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Around 7% of the Indian population suffers from IBS
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
A game changing solution for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated